Alpha Cognition
Alpha Cognition reported revenue of $10 million in fiscal 2025. Its operating margin was −221.7%. Free cash flow was −$21 million. The diluted share count rose 143.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Alpha Cognition does
Alpha Cognition is a drug company focused on diseases that damage the brain and nerves, such as Alzheimer's disease. Its one approved product is ZUNVEYL, a twice-daily tablet for adults with mild to moderate Alzheimer's dementia. The FDA approved it in July 2024, and the company launched it in the United States on March 19, 2025. ZUNVEYL belongs to the same class of drugs as donepezil (Aricept), which aim to ease memory and thinking symptoms rather than slow the disease.
The company sells ZUNVEYL through its own sales team, which targets doctors who treat patients in nursing homes and other long-term care. It has set the drug's list price for wholesalers at $820 per month and is negotiating coverage with insurers and pharmacy benefit managers, the firms that run drug plans. It competes with older drugs of the same type, most of them also sold as generics.
Outside the United States, it licensed ZUNVEYL in Asia (excluding Japan), Australia and New Zealand to CMS International Development and Management in a deal worth up to $44 million in upfront and milestone payments, plus royalties on sales. It also has early-stage programs, including ZUNVEYL combined with memantine, a version that dissolves under the tongue, and a treatment for thinking problems after concussion. The company has 71 full-time employees.
Its biggest risks, as it describes them
- Its business depends almost entirely on ZUNVEYL, its only approved product, winning over doctors, patients and insurers.
- Insurers and drug plans may not cover ZUNVEYL widely or pay enough for it, which would limit sales.
- It relies on outside suppliers to make ZUNVEYL, including in Taiwan, and supply could be interrupted.
- It has lost money since it began and may need to raise more capital to keep selling and developing its drugs.
- Its other programs are at an early stage and may never become approved products.
Income statement
Alpha Cognition lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 1 | 48 | 66 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | −567.4x | −114.1x | −4,630.3x |
| Current ratio | 0.7x | 15.0x | 8.7x |
| Quick ratio | 0.7x | 14.8x | 8.1x |
Cash flow
Projections
Project Alpha Cognition's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $7.6 million of Alpha Cognition shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Opaleye Management Inc.10% owner | Bought | 13,426 | $8.47 | $113,718 | Form 4 |
| Sep 24, 2026 | Opaleye Management Inc.10% owner | Bought | 18,337 | $8.57 | $157,148 | Form 4 |
| Sep 16, 2026 | Opaleye Management Inc.10% owner | Bought | 80,170 | $8.51 | $682,443 | Form 4 |
| Sep 15, 2026 | Opaleye Management Inc.10% owner | Bought | 3,375 | $8.54 | $28,822 | Form 4 |
| Sep 14, 2026 | Opaleye Management Inc.10% owner | Bought | 40,373 | $8.70 | $351,245 | Form 4 |
| Aug 21, 2026 | Robert James WillsDirector | Bought | 10,000 | $9.62 | $96,200 | Form 4 |
| Aug 3, 2026 | Opaleye Management Inc.10% owner | Bought | 50,000 | $8.00 | $400,000 | Form 4 |
| Jul 31, 2026 | Opaleye Management Inc.10% owner | Bought | 2,900 | $7.92 | $22,968 | Form 4 |
| Jul 24, 2026 | Opaleye Management Inc.10% owner | Bought | 130 | $7.90 | $1,027 | Form 4 |
| Jul 23, 2026 | Opaleye Management Inc.10% owner | Bought | 49,849 | $7.80 | $388,822 | Form 4 |
| Jul 22, 2026 | Opaleye Management Inc.10% owner | Bought | 150,237 | $7.83 | $1.2 million | Form 4 |
| Jun 26, 2026 | Opaleye Management Inc.10% owner | Bought | 152,336 | $6.40 | $974,950 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | — | — |
| Altman Z'' | 3.09 | 3.69 |
| Accruals ratio | −26.4% | −0.4% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Alpha Cognition side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | FY25 | — | −221.7% | −202.3% | — | — | — | |
| TScan Therapeutics | FY25 | 266.6% | −1,315.4% | −1,353.3% | — | — | 3 | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Prothena | FY25 | −92.8% | −2,216.4% | — | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | 10 |
| Revenue growth | — | — | — |
| Gross profit | — | — | 10 |
| Research and development | 5 | 4 | 2 |
| Operating income | −10 | −12 | −23 |
| Net income | −14 | −15 | −21 |
| Diluted EPS (US$) | −3.84 | −2.04 | −1.18 |
| Diluted shares (millions) | 4 | 7 | 18 |
| Cash flow | |||
| Cash from operations | −9 | −8 | −20 |
| Capital expenditure | — | 0 | 0 |
| Free cash flow | — | −8 | −21 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 2 | 1 | 5 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 1 | 48 | 66 |
| Debt incl. finance leases | — | — | — |
| Total assets | 2 | 51 | 80 |
| Total liabilities | 7 | 12 | 17 |
| Shareholders' equity | −5 | 39 | 62 |
| Margins and ratios | |||
| Gross margin | — | — | 94.1% |
| Operating margin | — | — | −221.7% |
| Net margin | — | — | −202.2% |
| Free cash flow margin | — | — | −202.3% |
| Rule of 40 (growth + FCF margin) | — | — | — |
| Return on capital | — | — | — |
| Return on equity | — | −86.0% | −40.7% |
| Return on assets | — | −55.6% | −31.7% |
| Net debt to EBITDA | — | — | — |